RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 123 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,931,637 | +39.4% | 84,259 | +0.3% | 0.00% | 0.0% |
| Q2 2023 | $1,385,787 | +22.1% | 84,038 | +32.1% | 0.00% | +100.0% |
| Q1 2023 | $1,134,534 | -38.7% | 63,595 | 0.0% | 0.00% | -66.7% |
| Q4 2022 | $1,851,886 | +18.9% | 63,595 | 0.0% | 0.00% | +50.0% |
| Q3 2022 | $1,558,077 | +686.9% | 63,595 | +269.4% | 0.00% | – |
| Q1 2022 | $198,000 | +15.1% | 17,216 | 0.0% | 0.00% | – |
| Q4 2021 | $172,000 | -23.6% | 17,216 | -0.2% | 0.00% | – |
| Q3 2021 | $225,000 | -33.4% | 17,259 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $338,000 | -0.9% | 17,259 | +7.7% | 0.00% | 0.0% |
| Q1 2021 | $341,000 | -22.3% | 16,031 | +8.6% | 0.00% | 0.0% |
| Q4 2020 | $439,000 | +66.9% | 14,766 | +21.8% | 0.00% | 0.0% |
| Q3 2020 | $263,000 | -2.6% | 12,126 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $270,000 | +20.0% | 12,126 | -18.0% | 0.00% | 0.0% |
| Q1 2020 | $225,000 | -29.7% | 14,796 | +6.1% | 0.00% | 0.0% |
| Q4 2019 | $320,000 | – | 13,950 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |